A detailed history of China Universal Asset Management Co., Ltd. transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 6,877 shares of ITOS stock, worth $96,415. This represents 0.01% of its overall portfolio holdings.

Number of Shares
6,877
Previous 6,877 -0.0%
Holding current value
$96,415
Previous $94,000 1.06%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$9.89 - $13.64 $27,068 - $37,332
2,737 Added 66.11%
6,877 $94,000
Q4 2023

May 21, 2024

SELL
$8.57 - $11.06 $23,456 - $30,271
-2,737 Reduced 39.8%
4,140 $45,000
Q4 2023

Jan 23, 2024

BUY
$8.57 - $11.06 $27,561 - $35,568
3,216 Added 348.05%
4,140 $45,000
Q3 2023

May 21, 2024

BUY
$10.95 - $14.6 $4,982 - $6,643
455 Added 97.01%
924 $10,000
Q3 2023

Oct 30, 2023

BUY
$10.95 - $14.6 $4,982 - $6,643
455 Added 97.01%
924 $10,000
Q2 2023

May 21, 2024

SELL
$12.93 - $18.05 $168 - $234
-13 Reduced 2.7%
469 $6,000
Q2 2023

Jul 27, 2023

SELL
$12.93 - $18.05 $168 - $234
-13 Reduced 2.7%
469 $6,000
Q1 2023

May 21, 2024

BUY
$13.02 - $22.62 $1,575 - $2,737
121 Added 33.52%
482 $6,000
Q1 2023

Apr 27, 2023

BUY
$13.02 - $22.62 $1,575 - $2,737
121 Added 33.52%
482 $7,000
Q4 2022

May 21, 2024

SELL
$17.77 - $21.6 $115,789 - $140,745
-6,516 Reduced 94.75%
361 $7,000
Q4 2022

Jan 31, 2023

BUY
$17.77 - $21.6 $497 - $604
28 Added 8.41%
361 $7,000
Q3 2022

Oct 21, 2022

BUY
$18.6 - $27.25 $6,193 - $9,074
333 New
333 $6,000

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $499M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.